{
    "clinical_study": {
        "@rank": "104083", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "The objective of this survey is to evaluate effectiveness of EYLEA on Quality of Life (QOL).\n      The QOL is evaluated by using Japanese version (v.1.4 - interviewer administered format) of\n      National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and compared at\n      baseline and at the 6 and 12 months after start of EYLEA treatment."
        }, 
        "brief_title": "EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have been determined to start EYLEA treatment\n\n          -  Patients who are registered to Special drug use investigation of EYLEA for AMD(Trial\n             Number 15858)\n\n          -  Patients who have agreed with the patient informed consent\n\n        Exclusion Criteria:\n\n          -  Patients who have already received EYLEA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with subfoveal choroidal neovascular age-related macular degeneration"
            }
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756261", 
            "org_study_id": "16656", 
            "secondary_id": "EYL-AMD-QOL"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients treated with EYLEA under practical manner for AMD.", 
            "intervention_name": "Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "EYLEA", 
            "Age-Related Macular Degeneration", 
            "QOL"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Japan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Special Drug Use Investigation of EYLEA for Quality of Life", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Changes in mean NEI-VFQ-25 overall scores of patients after the first intravitreal(ITV) injection of EYLEA", 
            "safety_issue": "No", 
            "time_frame": "baseline and 6 or 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756261"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Changes in mean NEI-VFQ-25 subscale scores of patients after the first ITV injection of EYLEA", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 or 12 months"
            }, 
            {
                "measure": "Changes in mean NEI-VFQ-25 overall scores after the first ITV injection of EYLEA in subpopulations of patient background characteristics and status of EYLEA treatments, ie. Frequency, visual acuity, etc", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 or 12 months"
            }, 
            {
                "measure": "Changes in mean NEI-VFQ-25 subscale scores after the first ITV injection of EYLEA in subpopulations of patient background characteristics and status of EYLEA treatments, ie. Frequency, visual acuity, etc", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 or 12 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}